Literature DB >> 7812627

Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits.

M Chamelian1, A Lécrivain, A Robichaud, P du Souich.   

Abstract

1. The present study aimed to investigate the effect of dehydration and hyperosmolal hydration on the disposition of lignocaine and two of its metabolites, monoethylglycinexylidide (MEGX) and glycinexylidide (GX). 2. Lignocaine was infused to three groups of conscious rabbits: controls, rabbits previously deprived of water for 48 h and rabbits receiving an infusion of 2.5% NaCl. 3. In dehydrated and hyperosmolal-hydrated rabbits, plasma osmolality was 321 +/- 1 and 313 +/- 1 mOsm kg-1, respectively (P < 0.01 compared to controls, 285 +/- 1 mOsm kg-1). In dehydrated animals, baseline values of plasma arginine vasopressin (AVP) concentrations and plasma renin activity (PRA) were higher than in controls, i.e. 12.4 +/- 1.4 pg ml-1 and 15.4 +/- 1.7 ng AI ml-1 h-1 vs. 3.4 +/- 0.2 pg ml-1 (P < 0.01), and 5.1 +/- 0.6 ng AI ml-1 h-1 (P < 0.01), respectively; atrial natriuretic peptide (ANP) decreased from 55 +/- 11 to 32 +/- 4 pg ml-1 (P < 0.05). Compared to controls, hyperosmolal hydration only increased AVP to 15.5 +/- 0.7 pg ml-1 (P < 0.01). 4. Under both experimental conditions, lignocaine plasma concentrations were almost double (P < 0.01) those in controls, due to a lower systemic clearance, e.g. 54 +/- 3 and 59 +/- 1 vs. 96 +/- 5 ml min-1 kg-1, respectively. Plasma levels of MEGX increased (P < 0.01) only in dehydrated animals, although GX plasma concentrations were augmented (P < 0.01) about three fold in both groups of animals. The changes in lignocaine plasma concentrations were correlated with AVP levels (R2 = 0.5168, P<0.001).5. To document the effect of AVP on hepatic plasma flow, another group of rabbits received on separate occasions two doses of AVP (17 and 84 ng kg-1) while receiving an infusion of in docyanine green. AVP reduced hepatic plasma flow from 38.9 +/-2.7 ml min-1 to 19.6 +/-2.5 ml min-1 (P<0.01).The predicted maximal AVP-induced decrease in hepatic plasma flow was 19.6 ml min-1 kg- 1(Emax), and AVP concentration eliciting 50% of Em.. (ED50) was 28.7 pg ml-1.6 It is concluded that both dehydration and hyperosmolal hydration alter the disposition of lignocaine and two of its metabolites.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7812627      PMCID: PMC1510051          DOI: 10.1111/j.1476-5381.1994.tb16211.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  50 in total

1.  The effect of Pitressin on cardiac output coronary, hepatic, and intestinal blood flow.

Authors:  T DRAPANAS; C P CROWE; W K SHIM; W G SCHENK
Journal:  Surg Gynecol Obstet       Date:  1961-10

2.  Lidocaine in the prevention of primary ventricular fibrillation. A double-blind, randomized study of 212 consecutive patients.

Authors:  K I Lie; H J Wellens; F J van Capelle; D Durrer
Journal:  N Engl J Med       Date:  1974-12-19       Impact factor: 91.245

3.  Inhibition of hepatic drug metabolism by cyclic 3',5'-adenosine monophosphate.

Authors:  M Weiner; G G Buterbaugh; D A Blake
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1972-03

4.  Intestinal vasoconstriction following diuretic-induced volume depletion: role of angiotensin and vasopressin.

Authors:  J R McNeill
Journal:  Can J Physiol Pharmacol       Date:  1974-08       Impact factor: 2.273

5.  Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans.

Authors:  P D Thomson; K L Melmon; J A Richardson; K Cohn; W Steinbrunn; R Cudihee; M Rowland
Journal:  Ann Intern Med       Date:  1973-04       Impact factor: 25.391

6.  The tissue distribution, metabolism and excretion of lidocaine in rats, guinea pigs, dogs and man.

Authors:  J B Keenaghan; R N Boyes
Journal:  J Pharmacol Exp Ther       Date:  1972-02       Impact factor: 4.030

7.  Binding of anilide-type local anesthetics in human plasma. I. Relationships between binding, physicochemical properties, and anesthetic activity.

Authors:  G T Tucker; R N Boyes; P O Bridenbaugh; D C Moore
Journal:  Anesthesiology       Date:  1970-09       Impact factor: 7.892

8.  Preliminary characterization of an inhibitor of drug metabolism released in response to cyclic adenine nucleotides.

Authors:  M Weiner
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1973-09

9.  Studies on the mechanism of inhibition of drug biotransformation by cyclic adenine nucleotides.

Authors:  M Weiner; G G Buterbaugh; D A Blake
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1972-07

10.  Pharmacological activity, metabolism, and pharmacokinetics of glycinexylidide.

Authors:  J M Strong; D E Mayfield; A J Atkinson; B C Burris; F Raymon; L T Webster
Journal:  Clin Pharmacol Ther       Date:  1975-02       Impact factor: 6.875

View more
  1 in total

1.  Lack of presystemic metabolism of nifedipine in the rabbit.

Authors:  P du Souich; L Héroux; H Maurice; M Dépôt; G Caillé
Journal:  J Pharmacokinet Biopharm       Date:  1995-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.